Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer.
Yijiu RenHai TangJie ZhangYunlang SheXiaoting SunDong XieChang ChenPublished in: Therapeutic advances in medical oncology (2020)
Targeted neoadjuvant therapy is the best treatment for prolonging PFS. The neoadjuvant chemotherapy with platinum drugs was associated with the better OS benefits for patients with NSCLC, compared with surgery alone. There is no significant difference in the efficacy of neoadjuvant therapy for the stage IIIA N2 NSCLC.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- rectal cancer
- lymph node
- small cell lung cancer
- squamous cell carcinoma
- systematic review
- radiation therapy
- sentinel lymph node
- advanced non small cell lung cancer
- minimally invasive
- coronary artery bypass
- meta analyses
- stem cells
- randomized controlled trial
- early stage
- replacement therapy
- drug delivery
- cell therapy
- atrial fibrillation
- smoking cessation